Cargando…
Efficacy of FDA-Approved Anti-Inflammatory Drugs Against Venezuelan Equine Encephalitis Virus Infection
Venezuelan equine encephalitis virus (VEEV) is a category B select agent pathogen that can be aerosolized. Infections in murine models and humans can advance to an encephalitic phenotype which may result in long-term neurological complications or death. No specific FDA-approved treatments or vaccine...
Autores principales: | Risner, Kenneth, Ahmed, Aslaa, Bakovic, Allison, Kortchak, Stephanie, Bhalla, Nishank, Narayanan, Aarthi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6950191/ https://www.ncbi.nlm.nih.gov/pubmed/31842327 http://dx.doi.org/10.3390/v11121151 |
Ejemplares similares
-
Synthetic Host Defense Peptides Inhibit Venezuelan Equine Encephalitis Virus Replication and the Associated Inflammatory Response
por: Ahmed, Aslaa, et al.
Publicado: (2020) -
Venezuelan Equine Encephalitis Virus nsP3 Phosphorylation Can Be Mediated by IKKβ Kinase Activity and Abrogation of Phosphorylation Inhibits Negative-Strand Synthesis
por: Bakovic, Allison, et al.
Publicado: (2020) -
Inhibitors of Venezuelan Equine Encephalitis Virus Identified Based on Host Interaction Partners of Viral Non-Structural Protein 3
por: Bakovic, Allison, et al.
Publicado: (2021) -
Inhibition of Venezuelan Equine Encephalitis Virus Using Small Interfering RNAs
por: Haikerwal, Amrita, et al.
Publicado: (2022) -
The transcriptional landscape of Venezuelan equine encephalitis virus (TC-83) infection
por: Yao, Zhiyuan, et al.
Publicado: (2021)